jCyte

20 articles about jCyte

• jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in the Second Half of 2024

  2/21/2024

  jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell ® for Retinitis Pigmentosa in the Second Half of 2024.

• jCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer

  7/12/2022

  jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the expansion of the company’s leadership team with the appointment of Dr. Stewart Craig as Chief Technology Officer.

• jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy

  11/15/2021

  jCyte, Inc., announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its Phase 2b study, the largest randomized clinical trial ever conducted in RP for a locally administered investigational treatment.

• jCyte Announces Appointment of Peter C. Kuper as Senior Vice President of Finance and Information Technology

  11/2/2021

  jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s leadership team with the appointment of Peter Kuper as Senior Vice President of Finance and Information Technology.

• jCyte Announces Appointment of John Pollack, MD, FASRS, as Chief Medical Officer

  10/19/2021

  jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s executive management team with the appointment of John Pollack, MD, FASRS, as the company’s first Chief Medical Officer (CMO).

• jCyte Announces Expansion of Role for Chief Commercial Officer Samir Mody

  10/14/2021

  jCyte, Inc. today announced the expansion of the role of Dr. Samir Mody. In addition to his Chief Commercial Officer responsibilities focused on preparing for the North American launch of jCell, Dr. Mody will now also assume leadership for the Global Pricing, Health Economics, and Reimbursement functions for jCyte.

• jCyte Announces Appointment of R. Heath Coats as Vice President of CMC, Regulatory Compliance and Quality Control

  10/6/2021

  jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the expansion of the company’s leadership team with the appointment of R. Heath Coats as Vice President of CMC, Regulatory Compliance and Quality Control.

• jCyte® Announces Appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations

  9/21/2021

  jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the Company’s leadership team with the appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations.

• jCyte Announces Appointment of Adrian Morris as Chief Development Officer

  7/6/2021

  jCyte, Inc . announced the continued expansion of the company’s executive management team with the appointment of Adrian Morris as Chief Development Officer.

• jCyte Announces Appointment of Dr. Adam Walsh as Chief Financial Officer

  6/22/2021

  jCyte, Inc. announced the further expansion of the company’s executive management team with the appointment of Adam Walsh, M.D. as Chief Financial Officer.

• jCyte Announces Appointment of John Sholar as General Counsel

  5/25/2021

  jCyte, Inc. , a biotech company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the further expansion of the company’s executive management team with the appointment of John Sholar as General Counsel. Mr. Sholar brings to jCyte more than 20 years of industry experience, serving as the head of North American legal

• jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy

  5/3/2021

  jCyte, Inc . today announced presentations at the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Following the Phase 2b headline results of jCell therapy in retinitis pigmentosa (RP) first presented at the American Society of Retinal Specialists (ASRS) Annual Meeting, further detailed analyses from this study, the largest randomized clinical trial ever conducted

• 

  jCyte Announces Promising Phase IIb Results for Allogeneic Retinal Stem Cell Therapy

  5/1/2021

  jCyte Inc. presented the results from its Phase IIb study and a detailed analysis of the study’s optical coherence tomography (OCT) data last week at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

• jCyte Announces Expansion of its Executive Leadership Team with Appointments in Commercial, Clinical and Manufacturing Operations

  2/16/2021

  Company appoints Dr. Samir Mody as Chief Commercial Officer, Dr. Friedrich Asmus as SVP, Clinical Development & Medical Affairs and Joel Centeno as SVP, Manufacturing, Quality & Supply Chain.

• jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa

  7/27/2020

  Phase 2b results show that treatment with jCell was well-tolerated and demonstrated encouraging evidence of potential benefit in patients as an investigational treatment for retinitis pigmentosa agnostic to genetic subtype Based on these results, jCyte plans to initiate a pivotal study in 2021 jCell is a first-in-class investigational treatment which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Dr

• jCyte Inc. Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting

  7/7/2020

  jCyte Inc. , a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today that results from the Phase 2b clinical trial of jCell in retinitis pigmentosa will be presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting, held July 24-26, 2020. jCell is a first-in-class investigation

• jCyte Inc. Announces Scientific Advisory Board with Distinguished Retinal Physicians

  6/30/2020

  jCyte Inc ., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory Board (SAB) comprised of world-renowned retinal physicians to provide external scientific review and high-level counsel on the Company’s research and development programs. The SAB will continue to work closely with the jCyte leadership team, as the Comp

• jCyte Presents Results of Clinical Testing in Retinitis Pigmentosa

  12/19/2017

  Presented by David S. Boyer, MD, at the annual Ophthalmology Innovation Summit in November, the 12-month study showed a favorable safety profile and indications of potential benefit.

• jCyte Receives Regenerative Medicine Advanced Therapy Designation

  5/2/2017

• Powered By CIRM Grant, jCyte Launches New Clinical Trial

  4/26/2017